Vivos Therapeutics to effect 1-for-25 reverse stock split

Vivos Therapeutics will effect a 1-for-25 reverse stock split of its issued and outstanding common stock, effective with the opening of trading on Friday, October 27, 2023. Vivos’ Common Stock will continue to trade on the Nasdaq Capital Market under the symbol “VVOS“. The new CUSIP number for the Common Stock following the Reverse Stock Split will be 92859E207. The Reverse Stock Split was approved at Vivos’ 2023 Annual Meeting of Stockholders on September 22, 2023. At such stockholder’s meeting, Vivos’ stockholders approved a proposal to authorize a reverse stock split of the Common Stock at a ratio of between 1-for-10 and 1-for-30, with the exact ratio to be determined by the Vivos’ board of directors in its sole discretion. Among other considerations, the Reverse Stock Split is intended to bring Vivos into compliance with the $1.00 minimum bid price requirement for maintaining the listing of its Common Stock on the Nasdaq Capital Market, and to make the prevailing prices of the Common Stock more attractive to a broader group of institutional investors. Vivos anticipates it will regain compliance with Nasdaq’s minimum bid price requirement if the Common Stock trades significantly above $1.00 for ten trading days following the effectiveness of the Reverse Stock Split.